Ulocuplumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | C-X-C chemokine receptor type 4 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1375830-34-4 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6486H9960N1720O2046S46 |
| Molar mass | 146.2 kg/mol |
Ulocuplumab[1] is a monoclonal antibody designed for the treatment of hematologic malignancies.[2]
This drug was developed by Bristol-Myers Squibb.
References
- ↑ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Ulocuplumab, American Medical Association.
This article is issued from Wikipedia - version of the 6/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.